Hong-Lin He1,2, Ying-En Lee3, Yow-Ling Shiue2, Sung-Wei Lee4, Li-Ching Lin5, Tzu-Ju Chen6, Ting-Feng Wu7, Chien-Feng Li6,7,8,9. 1. Department of Pathology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan. 2. Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan. 3. Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 4. Department of Radiation Oncology, Chi-Mei Medical Center, Liouying, Tainan, Taiwan. 5. Department of Radiation Oncology, Chi-Mei Medical Center, Tainan, Taiwan. 6. Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan. 7. Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan. 8. Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 9. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Abstract
AIMS: The aim of this study was to investigate the prognostic impact of group IIA phospholipase A2 (PLA2G2A) expression and its role in predicting the response to neoadjuvant concurrent cheomoradiotherapy (CCRT) in rectal cancer. METHODS AND RESULTS: Through analysing a public transcriptome of rectal cancers, the PLA2G2A gene was identified as a significant predictor for CCRT response. We validated the expression of PLA2G2A using immunohistochemistry in the pretreatment tumour specimens from 172 patients with rectal cancer. The results were correlated with clinicopathological features, tumour regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of PLA2G2A was associated with advanced pretreatment tumour status (P = 0.001), advanced pretreatment nodal status (P = 0.010), advanced post-treatment tumour status (P = 0.002) and lower tumour regression grade (P = 0.006). Furthermore, PLA2G2A expression was correlated negatively with gamma H2A histone family, member X (γ-H2AX) expression (P < 0.001, r = -0.580). More importantly, high expression of PLA2G2A emerged as an adverse prognostic factor for OS (P = 0.0190), DFS (P < 0.0001) and LRFS (P < 0.0001). In multivariate analysis, it remained independently prognostic for shorter DFS (P = 0.014) and LRFS (P = 0.012). CONCLUSIONS: High expression of PLA2G2A was associated with poor therapeutic response and worse survival in patients with rectal cancer receiving neoadjuvant CCRT, justifying PLA2G2A as an important marker to predict CCRT response and outcome.
AIMS: The aim of this study was to investigate the prognostic impact of group IIA phospholipase A2 (PLA2G2A) expression and its role in predicting the response to neoadjuvant concurrent cheomoradiotherapy (CCRT) in rectal cancer. METHODS AND RESULTS: Through analysing a public transcriptome of rectal cancers, the PLA2G2A gene was identified as a significant predictor for CCRT response. We validated the expression of PLA2G2A using immunohistochemistry in the pretreatment tumour specimens from 172 patients with rectal cancer. The results were correlated with clinicopathological features, tumour regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of PLA2G2A was associated with advanced pretreatment tumour status (P = 0.001), advanced pretreatment nodal status (P = 0.010), advanced post-treatment tumour status (P = 0.002) and lower tumour regression grade (P = 0.006). Furthermore, PLA2G2A expression was correlated negatively with gamma H2A histone family, member X (γ-H2AX) expression (P < 0.001, r = -0.580). More importantly, high expression of PLA2G2A emerged as an adverse prognostic factor for OS (P = 0.0190), DFS (P < 0.0001) and LRFS (P < 0.0001). In multivariate analysis, it remained independently prognostic for shorter DFS (P = 0.014) and LRFS (P = 0.012). CONCLUSIONS: High expression of PLA2G2A was associated with poor therapeutic response and worse survival in patients with rectal cancer receiving neoadjuvant CCRT, justifying PLA2G2A as an important marker to predict CCRT response and outcome.
Authors: Zhihong Gong; Jie Wang; Dan Wang; Matthew F Buas; Xuefeng Ren; Jo L Freudenheim; Steven A Belinsky; Song Liu; Christine B Ambrosone; Michael J Higgins Journal: Carcinogenesis Date: 2019-03-12 Impact factor: 4.944
Authors: Wang Da; Wu Yinhang; Zhuang Jing; Xu Jiamin; Gao Xinyi; Song Yongmao; Pan Yuefen Journal: J Interferon Cytokine Res Date: 2022-05 Impact factor: 3.657
Authors: Trine Line Hauge Okholm; Shashank Sathe; Samuel S Park; Andreas Bjerregaard Kamstrup; Asta Mannstaedt Rasmussen; Archana Shankar; Zong Ming Chua; Niels Fristrup; Morten Muhlig Nielsen; Søren Vang; Lars Dyrskjøt; Stefan Aigner; Christian Kroun Damgaard; Gene W Yeo; Jakob Skou Pedersen Journal: Genome Med Date: 2020-12-07 Impact factor: 11.117